Novartis Pluvictotm Shows Statistically Significant And Clinically Meaningful Radiographic Progression-Free Survival Benefit In Patients With Psma–Positive Metastatic Castration-Resistant Prostate Cancer

Novartis AG NOVN:

• NOVARTIS PLUVICTOTM SHOWS STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL RADIOGRAPHIC PROGRESSION-FREE SURVIVAL BENEFIT IN PATIENTS WITH PSMA–POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER